
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Holdings is a digital healthcare company that provides ambulatory cardiac monitoring services through its Zio System, which combines patch-based biosensors with cloud-based data analytics software. Management expects growth from expanding into the primary care and innovative channel markets, launching its Zio MCT product, and entering into new healthcare categories. Despite concerns around changes to CMS reimbursement criteria, the company saw record volumes and profitability in 2025, leading to strong revenue and EBITDA guidance for 2026. Factors that could drive further upside include higher growth in testing volumes, increased revenue, and growth in international markets. Potential risks include sales execution issues, competition, reimbursement changes, and additional equity offerings.
Bears say
iRhythm Holdings is facing a variety of challenges that could potentially hinder its growth and profitability. Amidst rising competition in the digital healthcare industry, the company's revenue growth has been slowing down and profitability remains low. Its 2026 outlook anticipates only 17-18% revenue growth and a low double-digit EBITDA margin, and with upcoming product launches not expected to have a significant impact on these metrics, the company may struggle to achieve its long-term revenue and profitability goals.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares